Forty Seven, Inc. to Present Initial Safety and Efficacy Data from Phase 1b Clinical Trial of 5F9 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome at 2019 ASCO Annual Meeting

Liz Kane
Impactful Strategy

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment